(Reuters) -Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state documents, company emails and interviews with ...

The South Korean government said Monday it plans to tighten regulations on the misuse of medications such as Wegovy and Saxenda, as growing numbers of people us

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives for weight loss include the injections Wegovy®, Mounjaro®, Zepbound®, …

Novo Nordisk has a significant presence in the U.S. manufacturing sector and is expanding its facility. The administration won't impose tariffs until negotiations are closed. The drugmaker is awaiting approval to market an oral medication for weight loss.